A Phase II Study of Maintenance Vorolanib and Atezolizumab in Patients With Extensive-stage SCLC
Latest Information Update: 30 Sep 2025
At a glance
- Drugs Atezolizumab (Primary) ; Vorolanib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 08 Sep 2025 Status changed from active, no longer recruiting to discontinued.
- 26 Aug 2025 Planned End Date changed from 5 Jul 2025 to 18 Aug 2025.
- 08 Dec 2022 Status changed from recruiting to active, no longer recruiting.